title: Management of rivaroxaban in relation to bodyweight and body mass index.
abstract: Being overweight or obese is associated with a higher individual risk of venous thromboembolism and poorer postprocedural outcomes after hip or knee replacement surgery. In addition, there is evidence that obesity represents a significant driving factor for the current and projected prevalence of atrial fibrillation. Rivaroxaban and other direct oral anticoagulants offer fixed-dose regimens for these indications. They do not require therapeutic drug monitoring or dose adjustment according to the weight of the patient. However, primary care physicians seem to be hesitant to accept the concept of a fixed-dose regimen for patients at extremes of weight, perhaps because of familiarity with weight-based dosing of other drugs including low molecular weight heparins. The main concerns related to unadjusted dosing are increased exposure in underweight patients leading to a risk of excessive bleeding and conversely to underanticoagulation of overweight patients. Rivaroxaban has shown similar efficacy and a similar or better safety profile compared with standard treatment for several venous and arterial indications, including venous thromboembolism, nonvalvular atrial fibrillation, and acute coronary syndrome. Prespecified subgroup analyses of patients stratified by weight or body mass index demonstrated outcomes that were consistent with the overall analysis and within each weight and body mass index group. The results suggest that standard-dose rivaroxaban can be safely prescribed in adult patients of all weights.
authors.affiliation: The Centre for Haemostasis and Thrombosis, St George's University Hospitals NHS Foundation Trust, Blackshaw Road, Tooting, London SW17 0QT, UK j.uprichard@nhs.net.
authors.forename: James
authors.initials: J
authors.lastname: Uprichard
mesh_terms: D015992:Body Mass Index; D001835:Body Weight; D017326:Clinical Trials, Phase III as Topic; D065427:Factor Xa Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D000069552:Rivaroxaban / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban
keywords: atrial fibrillation; bodyweight; oral anticoagulant; rivaroxaban; venous thromboembolism